Cybin Inc (CYBN) - Net Assets
Based on the latest financial reports, Cybin Inc (CYBN) has net assets worth CA$273.93 Million CAD (≈ $198.16 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$290.11 Million ≈ $209.86 Million USD) and total liabilities (CA$16.18 Million ≈ $11.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CYBN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$273.93 Million |
| % of Total Assets | 94.42% |
| Annual Growth Rate | 177.29% |
| 5-Year Change | 175.44% |
| 10-Year Change | N/A |
| Growth Volatility | 2304.22 |
Cybin Inc - Net Assets Trend (2020–2025)
This chart illustrates how Cybin Inc's net assets have evolved over time, based on quarterly financial data. Also explore Cybin Inc (CYBN) total assets for the complete picture of this company's asset base.
Annual Net Assets for Cybin Inc (2020–2025)
The table below shows the annual net assets of Cybin Inc from 2020 to 2025. For live valuation and market cap data, see how much is Cybin Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | CA$237.20 Million ≈ $171.59 Million |
-18.75% |
| 2024-03-31 | CA$291.93 Million ≈ $211.18 Million |
+505.23% |
| 2023-03-31 | CA$48.23 Million ≈ $34.89 Million |
-36.66% |
| 2022-03-31 | CA$76.16 Million ≈ $55.09 Million |
-11.57% |
| 2021-03-31 | CA$86.12 Million ≈ $62.30 Million |
+5847.38% |
| 2020-03-31 | CA$1.45 Million ≈ $1.05 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cybin Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33855800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$576.57 Million | 243.07% |
| Total Equity | CA$237.20 Million | 100.00% |
Cybin Inc Competitors by Market Cap
The table below lists competitors of Cybin Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Sanmao Enterprise Group Co Ltd A
SHG:600689
|
$301.57 Million |
|
Korea Environment Technology Co. LTD
KQ:029960
|
$301.63 Million |
|
Karmarts Public Company Limited
BK:KAMART
|
$301.65 Million |
|
WITHSECURE
HE:WITH
|
$301.75 Million |
|
Byggmax Group AB
ST:BMAX
|
$301.25 Million |
|
Materialise NV
F:06MA
|
$301.24 Million |
|
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
|
$301.18 Million |
|
Pro Real Estate Investment Trust
TO:PRV-UN
|
$301.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cybin Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 291,927,000 to 237,200,000, a change of -54,727,000 (-18.7%).
- Net loss of 113,137,000 reduced equity.
- New share issuances of 20,487,000 increased equity.
- Other factors increased equity by 37,923,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-113.14 Million | -47.7% |
| Share Issuances | CA$20.49 Million | +8.64% |
| Other Changes | CA$37.92 Million | +15.99% |
| Total Change | CA$- | -18.75% |
Book Value vs Market Value Analysis
This analysis compares Cybin Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.74x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 757.03x to 0.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | CA$0.01 | CA$8.35 | x |
| 2021-03-31 | CA$0.55 | CA$8.35 | x |
| 2022-03-31 | CA$0.46 | CA$8.35 | x |
| 2023-03-31 | CA$0.25 | CA$8.35 | x |
| 2024-03-31 | CA$14.59 | CA$8.35 | x |
| 2025-03-31 | CA$11.28 | CA$8.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cybin Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-47.70%) is above the historical average (-59.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -37.41% | -3729.17% | 0.01x | 1.07x | CA$-40.83 Million |
| 2022 | -88.81% | 0.00% | 0.00x | 1.10x | CA$-75.25 Million |
| 2023 | -98.46% | 0.00% | 0.00x | 1.12x | CA$-52.31 Million |
| 2024 | -26.75% | 0.00% | 0.00x | 1.03x | CA$-107.27 Million |
| 2025 | -47.70% | 0.00% | 0.00x | 1.09x | CA$-136.86 Million |
Industry Comparison
This section compares Cybin Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $4,755,581
- Average return on equity (ROE) among peers: -164.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cybin Inc (CYBN) | CA$273.93 Million | -37.41% | 0.06x | $301.37 Million |
| Appili Therapeutics Inc (APLI) | $4.87 Million | -81.69% | 0.48x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $10.57 Million | -166.31% | 1.08x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $141.48K | -593.02% | 3.59x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-247.66K | 0.00% | 0.00x | $6.98 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $5.11 Million | -84.55% | 0.14x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $2.98 Million | -302.25% | 0.65x | $116.58 Million |
| Hemostemix Inc (HEM) | $4.84 Million | -81.34% | 0.10x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $295.22K | -138.30% | 0.09x | $1.13 Million |
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more